liver fibrosis

[Experimental Cell Research] Scientists characterized the consequence of CCAAT/enhancer binding protein α overexpression on the expression of proteins LC3B, P62, ATG5 and Beclin1 which were related to autophagy in hepatic stellate cells.

[Cell Metabolism] Using cell-type-resolved genomics, scientists showed that comprehensive alterations in hepatocyte genomic and transcriptional settings during non-alcoholic steatohepatitis progression, led to a loss of hepatocyte identity.

[Communications Biology] The antifibrotic effect of auranofin was assessed in thioacetamide- and carbon tetrachloride-induced liver fibrosis models. Hepatic stellate cell, bone marrow-derived macrophage, kupffer cell, and hepatocyte were used to examine the underlying mechanism of auranofin.

[Scientific Reports] Ferroportin downregulation in hepatic cells increased the levels of the M2 markers CD206, TGF- β, VEGF, MMP-9, Laminin, Collagen, IL-4 and IL-10.

[Scientific Reports] Researchers clarified the intestinal absorption kinetics of dietary palmitic acid (PA) and the effect of trans-portal PA on the activation of hepatic stellate cells involved in liver fibrosis in nonalcoholic steatohepatitis.

[Dicerna Pharmaceuticals, Inc] Dicerna Pharmaceuticals, Inc. announced it has initiated patient dosing in the Company’s Phase II ESTRELLA trial of belcesiran, an investigational GalXC™ RNAi therapeutic candidate for the treatment of alpha-1 antitrypsin deficiency-associated liver disease.